INT10516

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.79
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 30
Total Number 30
Disease Relevance 7.54
Pain Relevance 2.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Vwf) cell adhesion (Vwf) endoplasmic reticulum (Vwf)
proteinaceous extracellular matrix (Vwf) molecular_function (Vwf) response to stress (Vwf)
Anatomy Link Frequency
plasma 4
platelet 4
endothelial cells 3
neuronal 1
primary neurons 1
Vwf (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Angina 30 100.00 Very High Very High Very High
ischemia 3 99.94 Very High Very High Very High
aspirin 8 99.06 Very High Very High Very High
Migraine 4 98.88 Very High Very High Very High
Inflammation 35 97.80 Very High Very High Very High
imagery 3 91.24 High High
rheumatoid arthritis 89 90.64 High High
Potency 7 88.72 High High
Neuropeptide 245 81.12 Quite High
analgesia 1 64.36 Quite High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 30 100.00 Very High Very High Very High
Cv Unclassified Under Development 5 99.94 Very High Very High Very High
Myocardial Infarction 15 99.46 Very High Very High Very High
Acute Coronary Syndrome 4 99.04 Very High Very High Very High
Death 2 99.00 Very High Very High Very High
Headache 4 98.88 Very High Very High Very High
Infarction 3 98.88 Very High Very High Very High
INFLAMMATION 36 97.80 Very High Very High Very High
Cardiovascular Disease 28 97.20 Very High Very High Very High
Hemolysis 3 92.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
OBJECTIVES: We tested the hypothesis that different anticoagulant treatments may produce different platelet effects and von Willebrand factor (vWf) release in unstable angina.
Localization (release) of vWf in platelet associated with angina
1) Confidence 0.79 Published 2000 Journal J. Am. Coll. Cardiol. Section Abstract Doc Link 10898421 Disease Relevance 0.17 Pain Relevance 0.17
OBJECTIVES: We tested the hypothesis that different anticoagulant treatments may produce different platelet effects and von Willebrand factor (vWf) release in unstable angina.
Localization (release) of von Willebrand factor in platelet associated with angina
2) Confidence 0.79 Published 2000 Journal J. Am. Coll. Cardiol. Section Abstract Doc Link 10898421 Disease Relevance 0.17 Pain Relevance 0.17
INTRODUCTION: To evaluate the participation of the vessel wall in the pathogenesis of migraine attack, we measured the plasma levels of von Willebrand factor (vWF), a protein secreted from the endothelial cells.
Localization (secreted) of vWF in plasma associated with migraine
3) Confidence 0.79 Published 1995 Journal Acta Neurol. Scand. Section Abstract Doc Link 7639074 Disease Relevance 0.17 Pain Relevance 0.17
INTRODUCTION: To evaluate the participation of the vessel wall in the pathogenesis of migraine attack, we measured the plasma levels of von Willebrand factor (vWF), a protein secreted from the endothelial cells.
Localization (secreted) of von Willebrand factor in plasma associated with migraine
4) Confidence 0.79 Published 1995 Journal Acta Neurol. Scand. Section Abstract Doc Link 7639074 Disease Relevance 0.17 Pain Relevance 0.17
Then the sections were incubated in rabbit antiserum directed against von Willebrand factor (vWf) (1:200, Chemicon) overnight at 4°C.
Localization (directed) of vWf
5) Confidence 0.71 Published 2008 Journal Acta Histochemica et Cytochemica Section Body Doc Link PMC2576503 Disease Relevance 0.05 Pain Relevance 0
These detection techniques include: histochemical assays that target enzymes enriched in blood vessels [3, 18], immunohistochemistry for vascular associated antigens (i.e. von Willebrand factor: a substance synthesised by, stored in, and released by endothelial cells) [2, 9, 20], perfusion with ink [1, 5], and use of fluorescein sodium [14, 21, 28].
Localization (released) of von Willebrand factor in endothelial cells
6) Confidence 0.71 Published 2008 Journal Acta Histochemica et Cytochemica Section Body Doc Link PMC2576503 Disease Relevance 0.12 Pain Relevance 0.05
Then the sections were incubated in rabbit antiserum directed against von Willebrand factor (vWf) (1:200, Chemicon) overnight at 4°C.
Localization (directed) of von Willebrand factor
7) Confidence 0.71 Published 2008 Journal Acta Histochemica et Cytochemica Section Body Doc Link PMC2576503 Disease Relevance 0.05 Pain Relevance 0
RESULTS: The release of vWf over the first 48 h (delta vWf) did not relate to the baseline clinical characteristics.
Localization (release) of vWf
8) Confidence 0.70 Published 2000 Journal J. Am. Coll. Cardiol. Section Body Doc Link 10898421 Disease Relevance 0.07 Pain Relevance 0
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.
Localization (release) of von Willebrand factor associated with aspirin and angina
9) Confidence 0.70 Published 2000 Journal J. Am. Coll. Cardiol. Section Title Doc Link 10898421 Disease Relevance 0.10 Pain Relevance 0.24
Moreover, the four different anticoagulant treatments tested here do not provide the same protection with regards to vWf release, which may have important prognostic implications and explain different results observed in recent clinical trials.


Localization (release) of vWf
10) Confidence 0.70 Published 2000 Journal J. Am. Coll. Cardiol. Section Body Doc Link 10898421 Disease Relevance 0 Pain Relevance 0
Anticoagulant drugs play a key role in stabilization of unstable angina, but they may not have the same efficacy and the same effects on acute vWf release.
Localization (release) of vWf
11) Confidence 0.70 Published 2000 Journal J. Am. Coll. Cardiol. Section Body Doc Link 10898421 Disease Relevance 0.09 Pain Relevance 0
RESULTS: The release of vWf over the first 48 h (delta vWf) did not relate to the baseline clinical characteristics.
Localization (release) of vWf
12) Confidence 0.61 Published 2000 Journal J. Am. Coll. Cardiol. Section Body Doc Link 10898421 Disease Relevance 0.07 Pain Relevance 0
Thus, given the amount of peptide release (18.2 fold less secretion of VWF-AgRP83-132 than flAgRP) and potencies (VWF-AgRP83-132 approximately 3 times less potent than flAgRP) our results are in agreement with the study by Creemers et al. that VWF-AgRP83-132 is 6 times more potent than flAgRP.
Localization (release) of VWF-AgRP83-132
13) Confidence 0.59 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC2928777 Disease Relevance 0 Pain Relevance 0.04
Both LMWHs reduced the release of vWF in plasma (as well as C-reactive protein) compared with UFH.
Localization (release) of vWF in plasma
14) Confidence 0.56 Published 2003 Journal Am. J. Cardiol. Section Abstract Doc Link 12686329 Disease Relevance 0.92 Pain Relevance 0.54
Multivariate analysis identified increased plasma levels of von Willebrand factor (vWF) and decreased platelet levels of glycoprotein Ib/IX complexes as independent predictors of 1-month adverse outcome (a composite of death, myocardial infarction, and recurrent ischemia). vWF release was strongly related to and may have been released by inflammation as measured by C-reactive protein.
Localization (release) of vWF in platelet associated with inflammation, ischemia, myocardial infarction and death
15) Confidence 0.56 Published 2003 Journal Am. J. Cardiol. Section Abstract Doc Link 12686329 Disease Relevance 0.97 Pain Relevance 0.55
Thus, given the amount of peptide release (18.2 fold less secretion of VWF-AgRP83-132 than flAgRP) and potencies (VWF-AgRP83-132 approximately 3 times less potent than flAgRP) our results are in agreement with the study by Creemers et al. that VWF-AgRP83-132 is 6 times more potent than flAgRP.
Localization (secretion) of VWF-AgRP83-132
16) Confidence 0.52 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC2928777 Disease Relevance 0 Pain Relevance 0.04
First we investigated if the vectors with the VWF signal peptide are secreted into the medium and compared this with a vector with its endogenous signal peptide.
Localization (secreted) of VWF signal peptide
17) Confidence 0.52 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC2928777 Disease Relevance 0 Pain Relevance 0.08
To determine the amount of protein secreted into the medium of 293T cells transfected with flAgRP, VWF-AgRP83-132 and GFP a spot blot was performed.
Localization (secreted) of VWF-AgRP83-132
18) Confidence 0.52 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC2928777 Disease Relevance 0 Pain Relevance 0
Thus, given the amount of peptide release (18.2 fold less secretion of VWF-AgRP83-132 than flAgRP) and potencies (VWF-AgRP83-132 approximately 3 times less potent than flAgRP) our results are in agreement with the study by Creemers et al. that VWF-AgRP83-132 is 6 times more potent than flAgRP.
Localization (secretion) of VWF-AgRP83-132
19) Confidence 0.48 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC2928777 Disease Relevance 0 Pain Relevance 0.04
Localization of flAgRP and VWF-AgRP83-132 in primary neurons
Localization (Localization) of VWF-AgRP83-132 in primary neurons
20) Confidence 0.48 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC2928777 Disease Relevance 0.08 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox